Persbericht: Programma bekend van gebruikersevent GiLab Commit 2019
Amsterdam — 30 augustus 2019 — GitLab, het DevOps platform,... Lees verder →
- Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups - Clinically relevant improvements in platelet count ...
Lees verderCORK, Ireland, Sept. 20, 2019 /PRNewswire/ -- Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the ...
Lees verderLEIDEN, Netherlands, June 11, 2019 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") today announces that, following receipt of the Dutch investigating ...
Lees verderNot intended for U.S. media -- 48-week results provide additional evidence of relapse reduction for investigational evobrutinib -- Evobrutinib demonstrated ...
Lees verderNot intended for US, Canada and UK-based media DARMSTADT, Germany and NEW YORK, Feb. 16, 2019 /PRNewswire/ -- -- JAVELIN Renal 101 shows significant improvement in ...
Lees verderLONDON, August 3, 2018 /PRNewswire/ -- Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet ...
Lees verderTAIPEI, Taiwan, July 26, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today that it has successfully completed a Phase 1 multiple ...
Lees verderAMSTERDAM, July 19, 2018 /PRNewswire/ -- Norgine B.V. today announced that results from the PLENVU(R) Phase III MORA trial were published in ENDOSCOPY, a monthly peer-reviewed ...
Lees verderLONDON, July 9, 2018 /PRNewswire/ -- The most open and inclusive racing esports tournament on the planet - global participation, multiple platforms, the biggest games. Twelve ...
Lees verderTOKYO, June 29, 2018 /PRNewswire/ -- Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 ...
Lees verder